KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Shares Outstanding (Diluted Average): 2009-2024

Historic Shares Outstanding (Diluted Average) for Ionis Pharmaceuticals (IONS) over the last 9 years, with Dec 2024 value amounting to $149.5 million.

  • Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) rose 7.52% to $159.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.8 million, marking a year-over-year increase of 7.52%. This contributed to the annual value of $149.5 million for FY2024, which is 4.42% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Shares Outstanding (Diluted Average) of $149.5 million as of FY2024, which was up 4.42% from $143.2 million recorded in FY2023.
  • Ionis Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $149.5 million during FY2024, with a 5-year trough of $141.0 million in FY2021.
  • For the 3-year period, Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $144.9 million, with its median value being $143.2 million (2023).
  • Data for Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 4.42% (in 2024) over the last 5 years.
  • Over the past 4 years, Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $141.0 million in 2021, then increased by 0.59% to $141.8 million in 2022, then climbed by 0.95% to $143.2 million in 2023, then climbed by 4.42% to $149.5 million in 2024.